PARP inhibitors
Prostate Cancer Genomics Study IDs PARP Inhibitors as Potentially Beneficial to Black Men
Some genes were more frequently mutated in prostate cancers from Black men, but the researchers said that social inequities also lead to poorer health outcomes.
Personalis to Provide Immunogenomic Profiling for University of New Mexico Ovarian Cancer Study
The company will test samples from women treated with an investigational combination of AstraZeneca's PARP inhibitor olaparib and immunotherapy tremelimumab.
The group published results showing its method can faithfully recapitulate genome-wide measures of DNA repair deficiency using much smaller sequencing panels.
FDA Approves Myriad Genetics' BRACAnalysis CDx With Lynparza in Earlier Ovarian Cancer Setting
The test is now approved as a CDx for advanced ovarian cancer patients considering Lynparza as a first-line maintenance treatment.
FDA Approves Myriad Genetics BRCA CDx With Pfizer's Metastatic Breast Cancer Drug
The test is approved to gauge germline BRCA mutations in advanced breast cancer patients who may benefit from treatment with Pfizer's PARP inhibitor Talzenna.